Chronic News and Research

RSS

AMGA, AMGF announce grantees in COPD Best Practices Learning Collaborative

The American Medical Group Association (AMGA) and the American Medical Group Foundation (AMGF) today announced recipients of grants for quality improvement initiatives focusing on care management for patients with Chronic Obstructive Pulmonary Disease (COPD). Recipients are medical groups, IPAs, academic practices, and integrated delivery systems that responded to a request for proposals distributed in August 2010.

8 Dec 2010

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.

8 Dec 2010

Detection of blood biomarker cTnT associated with structural heart disease

With the use of a highly sensitive test, detection of the blood biomarker cardiac troponin T, a cardiac-specific protein, is associated with structural heart disease and an increased risk of all-cause death, according to a study in the December 8 issue of JAMA.

8 Dec 2010

Golden Living establishes in-house consulting pharmacy company

Golden Living has established a new, in-house consulting pharmacy company that will focus on improving medication safety and patient outcomes. Golden Clinical Rx Services is based on an innovative clinical pharmacist model that will make certified geriatric pharmacists (CGPs) part of the interdisciplinary clinical teams that care for Golden LivingCenter patients and will leverage technology to improve patient outcomes.

8 Dec 2010

Some progress, but big challenges remain in prevention of cardiovascular disease

'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).

8 Dec 2010

Novel therapy against hepatitis C disease

University of Maryland School of Pharmacy researchers have developed a mathematical model for choosing an appropriate dosage of the hepatitis medications for individual patients. The work helps explain why African American patients tend to not respond as well to the drugs as other patients.

8 Dec 2010

Private insurers more effective in controlling health care spending than Medicare

Private insurers appear to be more effective in controlling health care spending differences between two Texas cities than Medicare, according to researchers from The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. Researchers found that sharp disparities in per-capita Medicare healthcare spending between McAllen and El Paso were significantly diminished when private insurance paid for health care costs in the under-65 population.

8 Dec 2010

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Patients with chronic myeloid leukemia who were treated with nilotinib are found to be associated with better treatment adherence, less hospitalizations, and lower total health care costs than patients treated with dasatinib, according to a new study released by Analysis Group Inc., a leading provider of health care research and economic consulting.

8 Dec 2010

Study examines impact of poor care coordination on quality, cost of care in America

Many Americans seek medical treatment from a variety of care providers and often must play the role of informing each doctor what the others are recommending or prescribing. This fragmented experience of poorly coordinated care is due in part to a lack of consistent systems and processes in place to coordinate care across providers and facilities.

8 Dec 2010

School-based ASMA program helps adolescents improve asthma management, quality of life

A school-based intervention program designed for adolescents with asthma significantly improves asthma management and quality of life for the students who participate, and reduces asthma morbidity, according to researchers in New York City, who studied the effect of the program aimed at urban youth and their medical providers.

8 Dec 2010

Reduced salt intake prevents serious threats in diabetic patients

For patients living with diabetes, reducing the amount of salt in their daily diet is key to warding off serious threats to their health, a new review of studies finds.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

8 Dec 2010

Company reaches $28 million settlement for Medicare program

The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."

7 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

European summit agrees that lifestyle change is the only answer to heart disease

‘Some progress, but the big challenges remain’. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).

7 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Keryx Biopharmaceuticals, Inc. today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.

7 Dec 2010

Chronic News and Research

AMGA, AMGF announce grantees in COPD Best Practices Learning Collaborative

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Detection of blood biomarker cTnT associated with structural heart disease

Golden Living establishes in-house consulting pharmacy company

Some progress, but big challenges remain in prevention of cardiovascular disease

Novel therapy against hepatitis C disease

Private insurers more effective in controlling health care spending than Medicare

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Study examines impact of poor care coordination on quality, cost of care in America

School-based ASMA program helps adolescents improve asthma management, quality of life

Reduced salt intake prevents serious threats in diabetic patients

Researchers synthesize wound-healing peptides

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

Company reaches $28 million settlement for Medicare program

New sensitive blood test could determine unrecognized heart disease

European summit agrees that lifestyle change is the only answer to heart disease

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News